参麦注射液辅助治疗急性心肌梗死的临床研究

Clinical trial of shenmai injection in the treatment of acute myocardial infarction

目的观察参麦注射液辅助治疗急性心肌梗死的临床疗效及安全性。方法将72例急性心肌梗死患者随机分为对照组35例和试验组37例。对照组予以吸氧、抗凝、抗血小板等治疗;试验组在对照组治疗的基础上,予以静脉滴注参麦注射液20 mL qd。2组患者均治疗2周。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为89.19%(33/37例)和71.43%(25/35例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的左心室射血分数(LVEF)分别为(72.16±16.44)%,(58.43±20.06)%;E峰值分别为(88.40±8.89),(68.19±6.87)cm·s^(-1);E/A值分别为(1.27±0.13),(0.98±0.10),差异均有统计学意义(P<0.05)。治疗后,试验组和对照组的A峰值分别为(69.61±7.03),(69.58±7.01)cm·s^(-1),差异无统计学意义(P>0.05)。治疗期间,试验组发生的药物不良反应有口干、过敏、恶心,对照组发生的药物不良反应有口干、过敏、头痛。试验组和对照组的药物不良反应率分别为13.51%和8.57%,差异无统计学意义(P>0.05)。结论参麦注射液辅助治疗急性心肌梗死有很好的临床疗效,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of shenmai injection in the treatment of acute myocardial infarction. Methods A total of 72 patients with acute myocardial infarction were randomly divided into control group （n = 35 cases） and treatment group （n = 37 cases ） . Control group was given oxygen, anticoagulation, antiplatelet, and so on. Treatment group was treated with Shenmai injection 20 mL, on the basis of the control group. Two groups were treated for 2 weeks. The clinical efficacy and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 89. 19% （33/37 cases） and 71.43% （25/35 cases）, and the difference was statistically significant （P 〈0.05）. After treatment, the main indexes in the treatment and control groups were compared： the left ventricular ejection fractions （LVEF） were （72. 16 ±16.44）%, （58.43 ±20.06）% ; E peak were （88.40±8.89）, （68.19±6.87）cm·s^-1; E/Awere （1.27±0.13）, （ 0. 98 ± 0. 10）, with significant difference （ P 〈 0. 05 ）. After treatment, A peak in the treatment and control groups were （69.61± 7.03 ）, （69.58 ±7.01 ）cm·s^-1 without significant difference （P 〉0. 05）. The adverse drug reactions in treatment group were dry mouth, allergies and nausea, which in control group was dry mouth, allergies and headaches. The incidence of adverse drug reactions in treatment and control groups were 13.51% and 8. 57% without significant difference （P 〉0. 05）. Conclusion Shenmai injection has a good clinical efficacy and safety in treatment of acute myocardial infarction.